Genotyping of Specific SNPs to Stratify Prostate Cancer RiskTechnology #ua16-162
Questions about this technology? Ask a Technology Manager
- Christina Laukaitis Associate Professor, Medicine
- Virginia Ware
- Kelsey Guest Research Specialist, UACC
- Jason Wilder Assoc Professor & Chair, Biological Sciences
- Ronald Heimark Professor, Surgery
- Managed By
- Lisa Lin Licensing Manager (520) 626-6969
Title: Genotyping of specific SNPs to stratify prostate cancer risk.
Invention: The technology are several SNP (single nucleotide polymorphism) markers with high potential of clinical utility to identify patients that will develop locally advanced stages of prostate cancer.
Background: The worldwide elderly population is experiencing an increase in prostate cancer. For prostate cancer prognosis, PSA levels and biopsy are sometimes inconclusive, leaving doctors and patients a difficult decision on whether to do a prostatectomy or not. These SNP markers (related to microRNA splicing) identified by the inventing team will help them to make a more informative decision.
- Clinical prognosis markers to predict aggressive prostate cancer
- Provides strong biomarkers to predict a patient’s risk on developing aggressive prostate cancer.
- Aids in improving decision making for treatment options.